Novel targeted agents for gastric cancer

Journal of Hematology and Oncology

Volumn 5, Issue , 2012, Pages

  Liu, Lian ^a   Wu, Ning ^c   Li, Jin ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

^c Xuhui District Central Hospital   (China)

Author keywords

Gastric cancer; Monoclonal antibody; Targeted therapy; Tyrosine kinase inhibitor

Indexed keywords

APATINIB; BEVACIZUMAB; CAPECITABINE; CEDIRANIB; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; EVEROLIMUS; FLUOROPYRIMIDINE; FLUOROURACIL; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN; ONARTUZUMAB; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PROTEIN TYROSINE KINASE INHIBITOR; RAMUCIRUMAB; SCATTER FACTOR RECEPTOR; SORAFENIB; SUNITINIB; TRASTUZUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN; VORINOSTAT;

ADVANCED CANCER; ANGIOGENESIS; ARTICLE; CANCER CONTROL; CANCER GROWTH; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOGENESIS; DECREASED APPETITE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ESOPHAGUS CANCER; FATIGUE; HUMAN; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PATIENT MONITORING; PATIENT SELECTION; PERSONALIZED MEDICINE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIGNAL TRANSDUCTION; STOMACH CANCER; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; HUMANS; MOLECULAR TARGETED THERAPY; STOMACH NEOPLASMS;

EID: 84862256003     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-5-31     Document Type: Article

References (77)

1. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM, Int J Cancer 2010 127 2893 2917 10.1002/ijc.25516 21351269
2. Epidemiology of upper gastrointestinal malignancies. Crew KD, Neugut AI, Semin Oncol 2 (Pubitemid 39070265)
3. Chemotherapy for advanced gastric cancer. Wagner AD, Unverzagt S, Grothe W, Kleber G, Grothey A, Haerting J, Fleig WE, Cochrane Database Syst Rev 2010 http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004064.pub3/abstract
4. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, et al. Lancet 2010 376 687 697 10.1016/S0140-6736(10)61121-X 20728210
5. Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy. Yuan RK, David, Andrea Berg WL, J HEMATOL ONCOL 2009 2 45 10.1186/1756-8722-2-45 19860903
6. Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. Tan J, Cang S, Ma Y, Petrillo RL, Liu D, J Hematol Oncol 2010 3 5 10.1186/1756-8722-3-5 20132536
7. Folkman J, Angiogenesis. Annu Rev Med 2006 57 1 18
8. The biology of VEGF and its receptors. Ferrara N, Gerber HP, LeCouter J, Nat Med 2003 9 669 676 10.1038/nm0603-669 12778165 (Pubitemid 36749215)
9. Prognostic significance of VEGF expression in correlation with COX-2, microvessel density, and clinicopathological characteristics in human gastric carcinoma. Kolev Y, Uetake H, Iida S, Ishikawa T, Kawano T, Sugihara K, Ann Surg Oncol 2007 14 2738 2747 10.1245/s10434-007-9484-7 17687613 (Pubitemid 47460647)
10. Clinicopathological significance of platelet-derived growth factor (PDGF)-B and vascular endothelial growth factor-A expression, PDGF receptor-beta phosphorylation, and microvessel density in gastric cancer. Suzuki S, Dobashi Y, Hatakeyama Y, Tajiri R, Fujimura T, Heldin CH, Ooi A, BMC Cancer 2010 10 659 10.1186/1471-2407-10-659 21118571
11. Prognostic significance of expression of cyclooxygenase-2 and vascular endothelial growth factor in human gastric carcinoma. Shi H, Xu JM, Hu NZ, Xie HJ, World J Gastroenterol 2003 9 1421 1426 12854133 (Pubitemid 36992325)
12. Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients. Lieto E, Ferraraccio F, Orditura M, Castellano P, Mura AL, Pinto M, Zamboli A, De Vita F, Galizia G, Ann Surg Oncol 2008 15 69 79 10.1245/s10434-007-9596-0 17896140
13. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Maeda K, Chung YS, Ogawa Y, Takatsuka S, Kang SM, Ogawa M, Sawada T, Sowa M, Cancer 1996 77 858 863 10.1002/(SICI)1097-0142(19960301)77: 5<858::AID-CNCR8>3.0.CO;2-A 8608475 (Pubitemid 26061277)
14. The clinicopathological significance of tissue levels of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in gastric cancer. Kim SE, Shim KN, Jung SA, Yoo K, Lee JH, Gut Liver 2009 3 88 94 10.5009/gnl.2009.3.2.88 20431729
15. Relationship between the expression of iNOS, VEGF, tumor angiogenesis and gastric cancer. Song ZJ, Gong P, Wu YE, World J Gastroenterol 2002 8 591 595 12174362 (Pubitemid 34918647)
16. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. Shah MA, Ramanathan RK, Ilson DH, Levnor A, D'Adamo D, O'Reilly E, Tse A, Trocola R, Schwartz L, Capanu M, et al. J Clin Oncol 2006 24 5201 5206 10.1200/JCO.2006.08.0887 17114652 (Pubitemid 46631363)
17. Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. Shah MA, Jhawer M, Ilson DH, Lefkowitz RA, Robinson E, Capanu M, Kelsen DP, J Clin Oncol 2011 29 868 874 10.1200/JCO.2010.32.0770 21189380
18. A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers. El-Rayes BF, Zalupski M, Bekai-Saab T, Heilbrun LK, Hammad N, Patel B, Urba S, Shields AF, Vaishampayan U, Dawson S, et al. Ann Oncol 2010 21 1999 2004 10.1093/annonc/mdq065 20332133
19. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR, Lim HY, Yamada Y, Wu J, Langer B, et al. J Clin Oncol 2011 29 3968 3976 10.1200/JCO.2011.36.2236 21844504
20. Survival analysis according to disease subtype in AVAGAST: First-line capecitabine and cisplatin plus bevacizumab (bev) or placebo in patients (pts) with advanced gastric cancer. Shah MA, Van Cutsem E, Kan Y, Dakhil SR, Satoh T, Chin K, Bang Y, Bu L, Bilic G, Ohtsu A, J Clin Oncol(Meeting Abstracts) 2012 30 5 http://www.asco.org/ASCOv2/Meetings/Abstracts'&vmview=abst-detail- view&confID=115&abstractID=88735
21. Ramucirumab, a fully human mAb to the transmembrane signaling tyrosine kinase VEGFR-2 for the potential treatment of cancer. Krupitskaya Y, Wakelee HA, Curr Opin Investig Drugs 2009 10 597 605 19513949
22. YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo. Tian S, Quan H, Xie C, Guo H, Lu F, Xu Y, Li J, Lou L, Cancer Sci 2011 102 1374 1380 10.1111/j.1349-7006.2011.01939.x 21443688
23. A randomized, double-blind, multicenter, phase, three-arm, placebo-control study of apatinib as third-line treatment in patients with metastatic gastric carcinoma. Li J, Qin S, Xu J, Guo WJ, Xiong JP, Bai Y, Sun G, Yang Y, Wang L, Xu N, et al. J Clin Oncol (Meeting Abstracts) 2011 29 4019
24. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M, Mol Cancer Ther 2008 7 3129 3140 10.1158/1535-7163.MCT-08-0013 18852116
25. Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. Sun W, Powell M, O'Dwyer PJ, Catalano P, Ansari RH, J Clin Oncol 2010 28 2947 2951 10.1200/JCO.2009.27.7988 20458043
26. Sunitinib: from rational design to clinical efficacy. Chow LQ, Eckhardt SG, J Clin Oncol 2007 25 884 896 10.1200/JCO.2006.06.3602 17327610 (Pubitemid 350002890)
27. An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer. Moehler M, Mueller A, Hartmann JT, Ebert MP, Al-Batran SE, Reimer P, Weihrauch M, Lordick F, Trarbach T, Biesterfeld S, et al. Eur J Cancer 2011 47 1511 1520 10.1016/j.ejca.2011.04.006 21561763
28. Phase II study of sunitinib as second-line treatment for advanced gastric cancer. Bang YJ, Kang YK, Kang WK, Boku N, Chung HC, Chen JS, Doi T, Sun Y, Shen L, Qin S, et al. Invest New Drugs 2011 29 1449 1458 10.1007/s10637-010- 9438-y 20461441
29. Current status of cediranib: the rapid development of a novel anti-angiogenic therapy. Lindsay CR, MacPherson IR, Cassidy J, Future Oncol 2009 5 421 432 10.2217/fon.09.18 19450171
30. Phase I study of cediranib in combination with cisplatin plus fluoropyrimidine (S-1 or capecitabine) in Japanese patients with previously untreated advanced gastric cancer. Satoh T, Yamada Y, Muro K, Hayashi H, Shimada Y, Takahari D, Taku K, Nakajima TE, Shi X, Brown KH, et al. Cancer Chemother Pharmacol 2011 69 2 439 446 21853311
31. Targeting HER1/EGFR: a molecular approach to cancer therapy. Arteaga C, Semin Oncol 2003 30 3 14 14513432 (Pubitemid 36828623)
32. Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer. Matsubara J, Nishina T, Yamada Y, Moriwaki T, Shimoda T, Kajiwara T, Nakajima TE, Kato K, Hamaguchi T, Shimada Y, et al. Br J Cancer 2008 98 832 839 10.1038/sj.bjc.6604211 18231104 (Pubitemid 351272605)
33. EGFR and cancer prognosis. Nicholson RI, Gee JM, Harper ME, Eur J Cancer 2001 37 Suppl 4 9 15 11597399
34. Impact of insulin-like growth factor type 1 receptor, epidermal growth factor receptor, and HER2 expressions on outcomes of patients with gastric cancer. Matsubara J, Yamada Y, Hirashima Y, Takahari D, Okita NT, Kato K, Hamaguchi T, Shirao K, Shimada Y, Shimoda T, Clin Cancer Res 2008 14 3022 3029 10.1158/1078-0432.CCR-07-1898 18483367
35. Epidermal growth factor receptor (EGFR): mutational and protein expression analysis in gastric cancer. Mammano E, Belluco C, Sciro M, Mencarelli R, Agostini M, Michelotto M, Marchet A, Nitti D, Anticancer Res 2006 26 3547 3550 17094480 (Pubitemid 44701536)
36. Epidermal growth factor receptor (EGFR) expression is associated with a worse prognosis in gastric cancer patients undergoing curative surgery. Galizia G, Lieto E, Orditura M, Castellano P, Mura AL, Imperatore V, Pinto M, Zamboli A, De Vita F, Ferraraccio F, World J Surg 2007 31 1458 1468 10.1007/s00268-007- 9016-4 17516110 (Pubitemid 46945355)
37. Epidermal growth factor receptor expression correlates with poor survival in gastric adenocarcinoma from Mexican patients: a multivariate analysis using a standardized immunohistochemical detection system. Gamboa-Dominguez A, Dominguez-Fonseca C, Quintanilla-Martinez L, Reyes-Gutierrez E, Green D, Angeles-Angeles A, Busch R, Hermannstadter C, Nahrig J, Becker KF, et al. Mod Pathol 2004 17 579 587 10.1038/modpathol.3800085 15073595 (Pubitemid 38868426)
38. A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma. Chan JA, Blaszkowsky LS, Enzinger PC, Ryan DP, Abrams TA, Zhu AX, Temel JS, Schrag D, Bhargava P, Meyerhardt JA, et al. Ann Oncol 2011 22 1367 1373 10.1093/annonc/mdq604 21217058
39. Biweekly cetuximab and irinotecan as second-line therapy in patients with gastro-esophageal cancer previously treated with platinum. Schoennemann KR, Bjerregaard JK, Hansen TP, De Stricker K, Gjerstorff MF, Jensen HA, Vestermark LW, Pfeiffer P, Gastric Cancer 2011 14 219 225 10.1007/s10120-011-0031-7 21409520
40. Phase II study of cetuximab in combination with modified FOLFIRI in patients with advanced gastric cancer who failed first-line chemotherapy (EFFI study). Li J, Liu X, Wang BY, Guo WJ, Yin JL, Zhu XD, Zhang J, Liu T, J Clin Oncol (Meeting Abstracts) 2010 28 15 4107 http://www.asco.org/ASCOv2/Meetings/ Abstracts'&vmview=abst-detail-view&confID=74&abstractID=47762
41. Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer. Han SW, Oh DY, Im SA, Park SR, Lee KW, Song HS, Lee NS, Lee KH, Choi IS, Lee MH, et al. Br J Cancer 2009 100 298 304 10.1038/sj.bjc.6604861 19127259
42. Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study). Pinto C, Di FF, Barone C, Siena S, Falcone A, Cascinu S, Rojas LFL, Stella G, Schinzari G, Artale S, et al. Br J Cancer 2009 101 1261 1268 10.1038/sj.bjc.6605319 19773760
43. Cetuximab Combined With FOLFOX4 as the First-Line Treatment for Advanced Gastric Cancer: Report of 25 Cases from a Single Institution. Shi M, Ji J, Wu J, Ma T, Liu Y, Zhou CF, Su Y, Ye ZB, Zhang J, Zhu ZG, Hepatogastroenterology 2012 59 doi:LID-10.5754/hge11874
44. Oxaliplatin, irinotecan and cetuximab in advanced gastric cancer. A multicenter phase II trial (Gastric-2) of the Arbeitsgemeinschaft Medikamentose Tumortherapie (AGMT). Woll E, Greil R, Eisterer W, Bechter O, Fridrik MA, Grunberger B, Zabernigg A, Mayrbaurl B, Russ G, Dlaska M, et al. Anticancer Res 2011 31 4439 4443 22199312
45. Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Lordick F, Luber B, Lorenzen S, Hegewisch-Becker S, Folprecht G, Woll E, Decker T, Endlicher E, Rothling N, Schuster T, et al. Br J Cancer 2010 102 500 505 10.1038/sj.bjc.6605521 20068568
46. A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer. Kim C, Lee JL, Ryu MH, Chang HM, Kim TW, Lim HY, Kang HJ, Park YS, Ryoo BY, Kang YK, Invest New Drugs 2011 29 366 373 10.1007/s10637-009-9363-0 19997960
47. Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study. Moehler M, Mueller A, Trarbach T, Lordick F, Seufferlein T, Kubicka S, Geissler M, Schwarz S, Galle PR, Kanzler S, Ann Oncol 2011 22 1358 1366 10.1093/annonc/mdq591 21119032
48. A randomized phase II study of three standard chemotherapy regimens (ECF, IC, FOLFOX) plus cetuximab in metastatic esophageal and GE junction cancer. Enzinger PC, Burtness B, Hollis D, Niedzwiecki D, Ilson D, Benson AB, Mayer RJ, Goldberg RM, J Clin Oncol (Meeting Abstracts) 2010 4006 28 4006 CALGB 80403/ECOG 1206
49. Phase II study of cetuximab plus weekly cisplatin and 24-hour infusion of high-dose 5-fluorouracil and leucovorin for the first-line treatment of advanced gastric cancer. Yeh K, Hsu C, Hsu C, Lin C, Shen Y, Wu S, Chiou T, Chao Y, Cheng A, J Clin Oncol (Meeting Abstracts) 2009 27 4567 http://www.asco.org/ ASCOv2/Meetings/Abstracts'&vmview=abst-detail-view&confID= 65&abstractID=32650
50. Oxaliplatin, irinotecan, and cetuximab in advanced gastric cancer. First efficacy results of a multicenter phase II trial (AGMT Gastric-2) of the Arbeitsgemeinschaft Medikamentoese Tumortherapie (AGMT). Woell E, Greil R, Eisterer W, Fridrik M, Grünberger B, Zabernigg A, Mayrbäurl B, Russ G, Thaler J, J Clin Oncol (Meeting Abstracts) 2009 27 4538 http://www.asco.org/ ASCOv2/Meetings/Abstracts'&vmview=abst-detail-view&confID= 65&abstractID=31014
51. Results of docetaxel plus oxaliplatin (DOCOX) with or without cetuximab in patients with metastatic gastric and/or gastroesophagel junction adenocarcinoma: Results of a randomized phase II study. Richards DA, Kocs DM, Spira AI, McCollum AD, Boehm KA, Zhan F, Asmar L, J Clin Oncol (Meeting Abstracts) 2011 29 4015 http://www.asco.org/ASCOv2/Meetings/ Abstracts'&vmview=abst-detail-view&confID=102&abstractID=79320
52. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, et al. J Clin Oncol 2010 28 4697 4705 10.1200/JCO.2009.27.4860 20921465
53. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, Andre T, Chan E, Lordick F, Punt CJ, et al. J Clin Oncol 2010 28 4706 4713 10.1200/JCO.2009.27.6055 20921462
54. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. Di NF, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, et al. J Clin Oncol 2008 26 5705 5712 10.1200/JCO.2008.18.0786 19001320
55. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finding study for the prospective multicenter, randomized, phase II/III REAL-3 trial. Okines AF, Ashley SE, Cunningham D, Oates J, Turner A, Webb J, Saffery C, Chua YJ, Chau I, J Clin Oncol 2010 28 3945 3950 10.1200/JCO.2010.29.2847 20679619
56. HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value-conclusions from 924 cases of two independent series. Grabsch H, Sivakumar S, Gray S, Gabbert HE, Muller W, Cell Oncol 2010 32 57 65 20208134
57. Overexpression of Grb2/HER2 signaling in Chinese gastric cancer: their relationship with clinicopathological parameters and prognostic significance. Yu GZ, Chen Y, Wang JJ, J Cancer Res Clin Oncol 2009 135 1331 1339 10.1007/s00432-009-0574-8 19337752
58. c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. Allgayer H, Babic R, Gruetzner KU, Tarabichi A, Schildberg FW, Heiss MM, J Clin Oncol 2000 18 2201 2209 10829039 (Pubitemid 30350211)
59. Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models. Fujimoto-Ouchi K, Sekiguchi F, Yasuno H, Moriya Y, Mori K, Tanaka Y, Cancer Chemother Pharmacol 2007 59 795 805 10.1007/s00280-006-0337-z 17031648 (Pubitemid 46440603)
60. Suppression of tumor growth in human gastric cancer with HER2 overexpression by an anti-HER2 antibody in a murine model. Matsui Y, Inomata M, Tojigamori M, Sonoda K, Shiraishi N, Kitano S, Int J Oncol 2005 27 681 685 16077916
61. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, Fox JA, Semin Oncol 1999 26 60 70 10482195 (Pubitemid 29411434)
62. Bang Y, Chung H, Xu J, Lordick F, Sawaki A, Lipatov O, Al-Sakaff N, See C, Rueschoff J, Van Cutsem E, Pathological features of advanced gastric cancer (GC): Relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial 2009 27 4556 http://www.asco.org/ASCOv2/Meetings/Abstracts'&vmview=abst-detail- view&confID=65&abstractID=32974
63. Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer. Iqbal S, Goldman B, Fenoglio-Preiser CM, Lenz HJ, Zhang W, Danenberg KD, Shibata SI, Blanke CD, Ann Oncol 2011 22 2610 2615 10.1093/annonc/mdr021 21415234
64. Lapatinib+capecitabine in advanced gastric cancer: An open-label phase II study of non ERBB2-targeted disease. Lenz H, Zhang W, Kemner AM, Ann Oncol 2010 21 817
65. Defining the role of mTOR in cancer. Guertin DA, Sabatini DM, Cancer Cell 2007 12 9 22 10.1016/j.ccr.2007.05.008 17613433 (Pubitemid 47001784)
66. Phase I trial of capecitabine plus everolimus (RAD001) in patients with previously treated metastatic gastric cancer. Lim T, Lee J, Lee DJ, Lee HY, Han B, Baek KK, Ahn HK, Lee SJ, Park SH, Park JO, et al. Cancer Chemother Pharmacol 2011 68 255 262 10.1007/s00280-011-1653-5 21526353
67. Two-dose-level confirmatory study of the pharmacokinetics and tolerability of everolimus in Chinese patients with advanced solid tumors. Xu B, Wu Y, Shen L, Ye D, Jappe A, Cherfi A, Wang H, Yuan R, J Hematol Oncol 2011 4 3 10.1186/1756-8722-4-3 21232120
68. Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer. Doi T, Muro K, Boku N, Yamada Y, Nishina T, Takiuchi H, Komatsu Y, Hamamoto Y, Ohno N, Fujita Y, et al. J Clin Oncol 2010 28 1904 1910 10.1200/JCO.2009.26.2923 20231677
69. Phase III trial of everolimus (EVE) in previously treated patients with advanced gastric cancer (AGC): GRANITE-1. Van Cutsem E, Yeh K, Bang Y, Shen L, Ajani JA, Bai Y, Chung HC, Pan H, Chin K, Muro K, et al. J Clin Oncol (Meeting Abstracts) 2012 30 http://www.asco.org/ASCOv2/Meetings/Abstracts'&vmview= abst-detail-view&confID=115&abstractID=87843
70. MET signaling pathway: a rational target for cancer therapy. Appleman LJ, J Clin Oncol 2011 29 4837 4838 10.1200/JCO.2011.37.7929 22042966
71. Impact of MET amplification on gastric cancer: possible roles as a novel prognostic marker and a potential therapeutic target. Lee J, Seo JW, Jun HJ, Ki CS, Park SH, Park YS, Lim HY, Choi MG, Bae JM, Sohn TS, et al. Oncol Rep 2011 25 1517 1524 21424128
72. Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer. Graziano F, Galluccio N, Lorenzini P, Ruzzo A, Canestrari E, D'Emidio S, Catalano V, Sisti V, Ligorio C, Andreoni F, et al. J Clin Oncol 2011 29 4789 4795 10.1200/JCO.2011.36.7706 22042954
73. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. Lennerz JK, Kwak EL, Ackerman A, Michael M, Fox SB, Bergethon K, Lauwers GY, Christensen JG, Wilner KD, Haber DA, et al. J Clin Oncol 2011 29 4803 4810 10.1200/JCO.2011.35.4928 22042947
74. Up-regulated expression of Ezrin and c-Met proteins are related to the metastasis and prognosis of gastric carcinomas. Zhao J, Zhang X, Xin Y, Histol Histopathol 2011 26 9 1111 1120 21751142
75. Gene expression signature analysis identifies vorinostat as a candidate therapy for gastric cancer. Claerhout S, Lim JY, Choi W, Park YY, Kim K, Kim SB, Lee JS, Mills GB, Cho JY, PLoS One 2011 6 24662 10.1371/journal.pone.0024662 21931799
76. Identification of genes related to a synergistic effect of taxane and suberoylanilide hydroxamic acid combination treatment in gastric cancer cells. Chang H, Rha SY, Jeung HC, Jung JJ, Kim TS, Kwon HJ, Kim BS, Chung HC, J Cancer Res Clin Oncol 2010 136 12 1901 1913 10.1007/s00432-010-0849-0 20217129
77. Recent advances in gastrointestinal oncology-updates and insights from the 2009 annual meeting of the American Society of Clinical Oncology. Javle MH, Chung-Tsen, J HEMATOL ONCOL 2010 3 11 10.1186/1756-8722-3-11 20331897